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	Introduction:	 Coronavirus	 Disease	 2019	 (COVID-19)	 vaccines	 have	 an	
important	role	in	the	control	and	prevention	of	the	pandemic.	However,	
infection	after	vaccination,	though	uncommon,	has	been	reported	after	





workers	 (HCWs)	 from	May	 2021	 to	 July	 2021	 at	 Patan	 Hospital,	 Patan	
Academy	of	Health	Sciences,	Nepal	who	received	the	Covishield	vaccine.	
The	data	were	collected	using	Google	form	and	a	printed	questionnaire	on	
COVID	 19	 breakthrough	 infection	 ≥2w	 after	 vaccination.	 The	 rate	 of	
breakthrough	 infection,	 hospitalization,	 and	 its	 association	 with	 age,	





























There	 is	a	 small	percentage	of	 re-infection	of	
COVID-19	(caused	by	coronavirus	SARS-CoV-2),	
and	 breakthrough	 infection	 after	
vaccination.1,2	COVID-19	vaccines	help	control	
the	 pandemic	 by	 preventing	 infection,	
decreasing	its	severity	and	hospitalization.3,4		
	
A	 breakthrough	 infection	 after	 vaccination	 is	
the	detection	of	SARS-CoV-2	RNA	or	antigen	in	
a	 respiratory	 specimen	 ≥14	 d	 after	
vaccination.2	Breakthrough	infections	are	mild	
and	occur	in	0.03%-0.05%.5-7	Higher	incidence	
of	 13.3%	 (15	 out	 of	 107)	 among	 health	 care	
workers	(HCWs)	was	reported	in	Fortis,	India.8	
Nepal	 began	 COVID-19	 vaccination	 with	
Covishield	 first	 for	health	care	workers	on	27	
Jan	 2021.9	 Effectiveness	 of	 a	 vaccine,	 and	 its	
equitable	 distribution	 is	 important	 to	 control	
COVID-19.10		
	
This	 study	 aims	 to	 find	 out	 vaccine	
breakthrough	infection	among	HCWs	of	Patan	







This	 was	 a	 cross-sectional	 study	 conducted	
from	 May	 2021	 to	 Jul	 2021	 to	 find	 out	
breakthrough	 infection	 after	 the	
administration	 of	 Covishield	 (ChAdOx1	 nCoV-	
19	 Corona	 Virus	 Vaccine	 of	 AstraZeneca	
produced	by	Serum	Institute	of	 India)	COVID-
19	 vaccine	 among	 HCWs	 at	 PAHS	 in	
Kathmandu,	 Nepal.	 All	 HCWs	 from	 the	 main	
teaching	 hospital	 (Patan	 Hospital)	 and	 3-
schools	 (School	 of	 Medicine,	 Nursing	 and	
midwifery,	 Public	 Health)	 of	 PAHS	 were	










included	 an	 information	 sheet	 for	 proforma	
and	voluntary	participation.	Completion	of	the	
form	 was	 considered	 as	 consent.	 Data	
collection	via	print	questionnaire	was	used	for	
those	 participants	who	 did	 not	 know	how	 to	
use	an	electronic	device	to	fill	the	Google	form.	
The	 forms	 were	 distributed	 and	 collected	
within	 two	 days.	 For	 data	 collection,	
researchers	 from	 among	 the	 listed	
investigators	 (authors)	 were	 designated	 to	
cover	the	different	departments	of	HCWs.	Data	
collection	 required	 approximately	 10	 min	 of	
participants’	time.		
	
The	 study	 variables	 included	 HCWs	
demographics	 (gender,	 age,	 departments),	
number	 of	 vaccines	 (1st	 dose	 only	 or	
recommended	two	doses),	COVID-19	infection	





medical	 (doctors,	 nurses,	 paramedical	 staff),	
non-medical	 (administrative	 staff,	
housekeeping	 staff,	 support	 staff,	 teaching	
faculties,	 and	 students).	 Teaching	 faculties	
involved	 in	 clinical	 work	 were	 grouped	 as	
medical;	 administrative	 staff	 included	 office	
workers	 except	 for	 medical,	 paramedical,	
support,	teaching	staff;	support	staff	included	
housekeeping,	security,	driver,	and	other	than	
paramedical,	 administrative,	 and	 teaching	
staff.	
	
The	 breakthrough	 infection	 after	 COVID-19	
vaccination	was	defined	as	Polymerase	Chain	
Reaction	 (PCR)	 positive	 in	 a	 respiratory	
specimen	≥14	d	after	two	doses	of	Covishield.7	
Infection	 that	 occurred	 <14	 d	 of	 vaccination	
was	categorized	as	an	early	breakthrough.	The	
PCR	 data	 were	 verified	 by	 one	 of	 the	 co-
investigators	 from	 the	 laboratory	 at	 Patan	
Hospital,	PAHS.	
	
The	 Google	 form	 data	 were	 interpreted	 in	
Excel	and	analyzed	by	SPSS	for	frequencies	and	
percentages,	and	the	Chi-square	test	was	used	









Data	 were	 collected	 after	 obtaining	 ethical	
approval	 from	 the	 Institutional	 Review	
Committee	 of	 PAHS	 (Ref:	 drs2105281528).	
Confidentiality	was	maintained	by	not	sharing	
the	 data	 for	 any	 purpose	 other	 than	 this	
research.	 Data	 were	 saved	 in	 a	 password-
protected	 file	on	a	personal	 computer	of	 the	
researcher	 during	 data	 processing	 and	
thereafter	 deposited	 with	 the	 institution	 as	
required	by	 the	ethical	 committee/institution	
for	 storage	 of	 at	 least	 5	 y,	 accessible	 to	 the	









There	 were	 880	 participants	 (738	 google	
forms,	 142	 print	 forms)	 who	 completed	 the	
survey,	 a	 response	 rate	of	 60.2%	 (880	out	of	
1462	approached).	Google	form	response	rate	
was	 56.4%(738	 replied	 of	 1309),	 and	 print	
forms	response	was	92.8%	(142	of	153).	
	
Males	 were	 194(22%).	 The	 majority	 of	
participants	606(68.9%)	were	in	the	age	group	
20-40	 y.	 Medical	 HCWs	 (doctors,	 nurses,	
paramedics)	 were	 464(52.7%),	 non-medical	
(administrative,	 teaching,	 support	 staff,	 and	
students)	416(47.3%),	Table	1.		
Out	of	880	HCWs,	819(93.1%)	completed	 the	
recommended	 two	 doses	 of	 Covishield.	
Infection	after	the	1st	dose	and	before	the	2nd	
dose	 was	 164(18.7%	 of	 880);	 whereas	 after	
both	doses	was	131(16.0%	of	819),	Table	2.	
	
Demographic	 variables	 had	 no	 statistically	
significant	 association	 with	 breakthrough	
infections,	 Table	 3.	 Out	 of	 819	 HCWs	 who	
completed	 vaccination,	 241(27.3%)	 had	 a	
history	 of	 COVID-19	 infection	 before	 the	
vaccine,	 and	 out	 of	 these	 215(89.2%)	
completed	 both	 doses	 of	 Covishield.	 Out	 of	
639	who	did	not	have	COVID-19	infection	prior	
to	 vaccination	 604(94.5%)	 completed	 both	
doses	of	vaccine.	Out	of	215	who	had	infection	
prior	to	vaccine	24(11.1%)	had	a	breakthrough	
infection	while	 out	 of	 604	who	 did	 not	 have	
infection	 prior	 to	 vaccine	 58(9.6%)	 had	 a	



































Variable		 	 N	 %	
Age	in	y	 <20		 43	 4.9	
	 20-40	 606	 68.9	
	 41-60	 215	 24.4	
	 >60	 16	 1.8	
Gender	 Male	 194	 22.0	
	 Female		 686	 78.0	
HCWs	Medical	 Dr.	 49	 5.6	
	 Nurse	 350	 39.8	
	 Paramedics	 65	 7.4	
HCWs	Non-medical	 Administration	 32	 3.6	
	 Teaching	 35	 4.0	
	 Support	 198	 22.5	
	 Student	 151	 17.2	
Hospitalized	 	 74	 8.4	

















Table	 3:	 Association	 of	 demographic	 variables	 for	 breakthrough	 infection	 (N=83)	≥14	 d	 after	 Covishield	
among	HCWs	at	PAHS,	Nepal	
	
Variables	 Breakthrough	infection,	N=83	 X2	value	 p	value	
Age	≤40y	 60(72.3%)	 0.086	 0.770	
Age	>40y	 23(27.7%)	
Male	 24(28.9%)	 2.517	 0.113	
Female	 59(71.8%)	










After	1st	dose	 <14	d		 58	 26.9	 22	 3.6	
≥14	d		 39	 18.1	 33	 5.5	
After	2nd	dose	 <14	d		 23	 10.7	 23	 3.8	












Our	 survey	 among	 HCWs	 at	 PAHS,	 Nepal	
following	 the	 Covishield	 COVID-19	 vaccine	
revealed	 a	 breakthrough	 infection	 (≥14	 d	 of	
complete	vaccination)	of	83(10.1%)	confirmed	
by	 a	 PCR	 test.	We	 did	 not	 find	 a	 statistically	
significant	 difference	 in	 breakthrough	
infections	 among	 medical	 and	 non-medical	
HCWs.	 The	 breakthrough	 infection	 rate	 is	
higher	than	the	generally	reported	of	0.03%	to	
0.05%5,6,7,11	 and	 lower	 than	 13.3%(15/107)	
from	Fortis,	India.8	The	Fortis	report	was	after	
completion	 of	 vaccination	 (1/3rd	 received	
Covaxin	 and	 2/3rd	 Covishield)	 among	 HCWs	
(doctors,	 nurses,	 paramedical	 workers,	 and	
other	staff).	Such	a	high	rate	of	breakthrough	
infection	 could	 be	 due	 to	 virus	 variants,	 and	
the	 lack	 of	 further	 analysis	 separately	 for	
Covaxin	 and	 Covishield.	 Breakthrough	
infection	among	HCWs	was	0.97%	to	1.19%	in	
California	USA.5	The	breakthrough	infection	in	
the	 real	 world	 scenario	 during	 mass	
vaccination	 has	 been	 higher	 than	 (0.05%)	
reported	during	the	clinical	trials.5,12		
	
Our	 data	 show	 that	 only	 74(25%)	 out	 of	
295(164	after	1st	dose	and	before	2nd	dose	plus	
131	after	two	vaccine	doses)	were	hospitalized,	
for	 isolation	 or	 treatment.	 The	 hospital	 data	
show	 none	 required	 ventilator	 support	 and	
mortality	was	nil.	The	hospital	policy	has	been	
revised	 to	 admit	 only	 those	 who	 require	
oxygen	 support	 and	 further	 treatment	
otherwise	home	isolation	for	2w.	Most	of	the	
studies	 report	 breakthrough	 infections	 are	
mild.	 The	 Indian	Council	 of	Medical	Research	
(ICMR)	 reports	 9.8%	 of	 infections	 required	
hospitalization,	and	fatality	of	0.4%.13	Another	
Indian	 study	 reports	 only	 5.5%(6	 of	 108)	
breakthrough	 infections	 required	
hospitalization	for	mild	to	moderate	symptoms,	
none	 required	 oxygen	 or	 ICU	 care	 and	
mortality	was	nil.3	Similar	studies	among	HCWs	
from	India	found	breakthrough	infections	were	
11%(36	 infections	 out	 of	 326	HCWs)	 and	 the	
majority	 (94.4%)	 were	 mild,	 not	 requiring	
oxygen	therapy.4	Literature	and	our	findings	on	
breakthrough	infections	following	vaccines	are	




before	 vaccine	 rollout.	 The	 reinfection	 and	
breakthrough	 were	 higher	 in	 those	 who	 had	
infection	 prior	 to	 the	 vaccination	 and	 the	
breakthrough	rate	was	also	higher.	One	of	the	
studies	 has	 expressed	 COVID-19	 infection	 to	
confer	 greater	 immunity	 than	 vaccine14,	 yet	
another	 study	 has	 reported	 that	 with	 prior	
natural	 infection	 of	 COVID-19,	 they	were	 4.5	
times	 less	 likely	 to	 experience	 re-infection	




not	 evaluate	 the	 period	 of	 infection	 before	
vaccination.	 It	 has	 been	 observed	 that	 IgG	
antibody	peaks	approximately	after	25	days	of	
infection	 and	 remains	 detectable	 for	 at	 least	
120	days	of	infection.15	In	our	study,	the	rate	of	
infection	 decreased	 with	 subsequent	
vaccination,	 conferring	 the	 development	 of	
herd	 immunity.	 The	 development	 of	 herd	
immunity	 has	 been	 demonstrated	 in	 several	
studies,	even	in	cases	of	mild	infection16,17	and	




In	 our	 study,	 both	 with	 or	 without	 prior	
infection	 before	 vaccines,	 the	 reinfection	
and/or	 breakthrough	 infections	were	mild	 to	
moderate	 without	 severe	 or	 critical	 cases,	
none	required	ICU	care	or	ventilator	support.		
We	 found	 breakthrough	 infections	 (≥14	 d)	 in	
83(10.1%	of	819),	and	early	breakthrough,	i.e.,	
<14d	 in	 48	 (5.9%	 of	 819)	 after	 a	 complete	
vaccine	 of	 two	 doses.	 Infection	 after	 the	
incomplete	vaccine,	i.e.,	after	1st	and	before	2nd	
dose	 was	 higher	 occurring	 in	 164	 (18.9%).	
Thus,	 until	 full	 immunity	 is	 developed	 after	
vaccination,	 common	 measures	 of	 non-
pharmaceutical	 interventions	 (NPI)	 should	 be	
observed.	 In	a	 similar	 study	of	326	HCWs,	65	




after	 the	 vaccine	 occurred	 in	 189(0.8%	 of	
22,729	HCWs),	out	of	which	only	26	(13.8%	of	
















COVID-19	 vaccine	 breakthrough	 infection	 (of	
1,949	 out	 of	 123	 million)	 980	 (50%)	 were	
female.2	 The	 CDC	 argued	 that	 more	
breakthrough	infections	in	females	could	have	
been	 due	 to	 the	 tendency	 of	 women	 to	 get	
tested	 more	 than	 men.	 The	 CDC	 America	
revealed	 that	 among	 5,800	 breakthrough	
infections	 among	 77	 million	 vaccinated	
persons,	1/3rd	(29%)	were	asymptomatic,	396	
(6.8%)	required	hospitalization,	and	74	(1.3%)	
died	 from	 COVID-19.	 All	 ages	 were	 affected,	
but	 40%	 occurred	 in	 >60	 y,	 possibly	 more	
infection	due	to	virus	variants	of	concern	(VOC)	
B.1.351	 (SA	 variant).2,19	 The	 VOCs	 are	
increasingly	 responsible	 for	 more	 infections	
reported	 recently.10,18,20	 The	 European	
Medicines	 Agency	 (EMA)	 and	 the	European	
Centre	 for	 Disease	 Prevention	 and	 Control	
(ECDC)	strongly	recommend	vaccination21,	and	




the	 14	 traveler	 mountaineers,	 six	 were	
symptomatic	 while	 three	 required	
hospitalizations	 and	 a	 61-y	 with	 two-dose	
mRNA-1273	 had	 a	 breakthrough	 infection	 by	
Delta	variant	B.1.617.2.22	We	did	not	conduct	
genome	 sequencing	 due	 to	 lack	 of	 logistics.	
The	 ICMR	 found	 that	 >86%	 of	 the	
breakthrough	infections	were	due	to	the	Delta	
variant,	 9.8%	 required	 hospitalization	 with	 a	
fatality	of	0.4%.13	The	study	also	reported	that	




The	 Chinese	 Centre	 for	 Disease	 Control	 and	
Prevention	 (CCDC)	 in	 early	 Apr	 2021	 allowed	
mixing	vaccines	 to	boost	 immunity.23	Gao	Fu,	
the	head	of	the	CCDC	revealed	that	he	got	the	
3rd	 dose	 of	 different	COVID-19	 vaccines	 and	
that	a	booster	dose	may	protect	against	new	
variants.24	 The	 ICMR	 found	 that	 a	 mixed	
vaccination	 (among	 18	 UP	 residents	 who	
inadvertently	 received	 mixed	 doses	 of	
Covishield	and	Covaxin)	was	safe	and	possibly	
effective	against	VOCs.25	 In	Nepal	 there	 is	no	
policy	of	mixing	vaccines	as	of	yet.	
	
Vaccine	 coverage	 of	 70%	 is	 the	 minimum	 to	
control	 the	 ongoing	 pandemic,	 which	 also	






(commercial	 or	 political)	 deal	 maintain	 the	
equitable	 vaccines	 for	 the	 global	 good.27	
Vaccine	coverage	 is	 the	ultimate	measure	 for	





To	maintain	 a	 functional	 environment	 in	 the	
ongoing	 COVID-19	 pandemic,	 staged	
vaccination	 includes	 a	 priority	 for	 essential	
workforces	 like	 HCWs,	law	 enforcement,	
security,	 nursing	 homes,	 social	 welfare	
institutes,	 community	 services,	 energy,	 food,	
and	 transportation	 sectors,	 and	 overseas	
workers/students;	 followed	 by	 older	 adults,	
individuals	 with	 underlying	 health	 conditions	
and	pregnant	women	 to	 reduce	 the	 severity,	
and	 lastly	 extension	 to	 adults	 without	









have	 been	 confirmed.31	 Limitations	 of	 this	
study	 might	 be	 contributed	 by	 factors	 like	
missed	 asymptomatic	 individuals	 with	
breakthrough	infection	due	to	lack	of	policy	to	
test	 all	 vaccine	 recipients,	 and	 the	 causative	
VOCs	 genome	 sequencing	 for	 possible	 VOCs	
due	to	lack	of	resources.	However,	the	hospital	
data	 show	 that	 there	 was	 no	 severe	







support,	 and	 there	 was	 no	 mortality.	 This	
shows	 that	 vaccination	 has	 benefits	 and	
effectively	 reduces	 severe	 infection	 and	
mortality.	 Larger	 studies,	 preferably	 in	 the	
community,	with	a	diverse	population	and	with	
comorbidities	 may	 provide	 further	 data	 on	







COVID-19	 vaccination	 occurred	 with	 a	 low	
frequency	(10.1%)	among	health	care	workers	
at	 Patan	Academy	of	Health	 Sciences,	Nepal.	
The	 vaccine	 was	 effective;	 as	 breakthroughs	
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